TIDMAVO
RNS Number : 2937K
Advanced Oncotherapy PLC
31 August 2021
31 August 2021
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Result of GM, TVR and clarification re warrants
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
announces that at the General Meeting held earlier today, all
resolutions were passed.
Accordingly, the 88,854,641 new Ordinary shares in respect of
the Subscription and fee arrangements, details of which were set
out in the Company's announcement of 11 August 2021, will be issued
and are expected to be admitted to trading on AIM on 3 September
2021. The remaining 11,145,405 Subscription Shares are expected to
be admitted to trading on AIM on or around 1 October 2021.
The results of the proxy voting for the General Meeting are set
out below:
Resolution Total votes % of votes Total Votes % of votes Votes Withheld(3)
For(1) cast(2) Against cast(2)
1 120,246,315 99.77 273,099 0.23 0
------------ ----------- ------------ ----------- ------------------
2 120,459,943 99.95 59,471 0.05 0
------------ ----------- ------------ ----------- ------------------
Notes
1. Any proxy votes that were at the discretion of the Chairman
are included in the "Total Votes For" each resolution
2. Percentage of votes cast excludes Votes Withheld
3. Votes Withheld are not votes in law and do not count in the
number of votes counted for or against a resolution
Clarification regarding warrants
The following table summarises the warrants that remain in
issue. The details in the table below are in accordance with the
previous announcements made by the Company, although the dates of
two outstanding batches of warrants have been incorrectly reflected
in the last annual report due to a typographical error.
Issue Date Final date of exercise Exercise price Number of Warrants
------------ ------------------------ --------------- -------------------
20-Jul-17 19-Jul-22 25p 20,468,687
26-Apr-18 25-Apr-23 70p 1,000,000
31-May-18 11-Jun-22 50p 450,000
31-Aug-18 31-Aug-23 100p 2,617,312
07-May-19 07-May-24 100p 3,500,000
31-Oct-19 31-Aug-24 100p 385,000
28-Jun-20 28-Jun-25 50p 5,000,000
Total 33,420,999
-------------------------------------- --------------- -------------------
Further warrants are due to be granted in respect of the
Subscription on the dates falling six months after First Admission
and Second Admission, as detailed in the Company's announcement of
11 August 2021.
Total voting rights
The Company's issued share capital as at the date of this
announcement comprises 350,334,730 ordinary shares of 25p each,
with one voting right per share ("Ordinary Shares"). The Company
does not hold any ordinary shares in treasury and therefore the
total number of Ordinary Shares with voting rights in the Company
is 350,334,730.
On 3 September 2021, a further 88,854,641 Ordinary Shares will
be issued as detailed above. Therefore, from 3 September 2021 the
issued share capital of the Company will comprise 439,189,371
Ordinary Shares. The Company does not hold any Ordinary Shares in
treasury and therefore the total voting rights in the Company will
be 439,189,371. From 3 September 2021, the figure of 439,189,371
should be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure Guidance
and Transparency Rules.
Defined terms used in this announcement shall have the same
meaning as in the announcement of 11 August 2021 unless otherwise
defined herein.
- ENDS -
Notes for editors
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Tel: +44 (0) 20 3328 5656
Amrit Nahal / Matt Butlin (Sales and Corporate Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
FTI Consulting (Financial PR & IR) advancedoncotherapy@fticonsulting.com
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCMZGFRNMGGMZM
(END) Dow Jones Newswires
August 31, 2021 13:14 ET (17:14 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2023 to Apr 2024
